Bradley Bernstein

Bradley Bernstein, M.D., Ph.D., is a Professor of Pathology and Cell Biology at Harvard Medical School and Chair of Cancer Biology at Dana-Farber Cancer Institute. He holds the Richard and Nancy Lubin Family Chair and directs the Broad Institute’s Gene Regulation Observatory and Epigenomics Program. His research focuses on epigenetic mechanisms in development and cancer, including chromatin regulation, bivalent domains, and cancer epigenetics. He has pioneered technologies like ENCODE and advanced understanding of noncoding DNA’s role in gene regulation. His work spans cancer mechanisms, stem cell circuits, and therapeutic resistance. Notable contributions include identifying bivalent chromatin states and linking epigenetic changes to oncogene activation in gliomas.

Education: B.S. from Yale University (1992), M.D. and Ph.D. from University of Washington (1999), postdoctoral training at Harvard University. Affiliations include Dana-Farber Cancer Institute, Broad Institute, and Ludwig Institute.

Research Interests: Epigenetic gene regulation, chromatin structure, cancer epigenetics, developmental hierarchies, single-cell technologies, and translational applications in oncology. Key areas include bivalent domains, tumor self-renewal, and epigenetic therapies.

Awards: Richard and Nancy Lubin Family Chair, Ludwig Institute Investigator.

Advising & Grants: Mentor to numerous graduate students and postdocs. Leads large-scale consortia (e.g., ENCODE, BLUEPRINT). Active in technology development for epigenomic mapping.

Labs/Teams: Bernstein Lab at Dana-Farber and Broad Institute, Epigenomics Program, and Gene Regulation Observatory. Collaborates widely across academia and industry.